High-density lipoprotein functionality in coronary artery disease

American Journal of the Medical Sciences

Volumn 347, Issue 6, 2014, Pages 504-508

  Kosmas, Constantine E ^a   Christodoulidis, Georgios ^b   Cheng, Jeh Wei ^c   Vittorio, Timothy J ^d   Lerakis, Stamatios ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ST FRANCIS HOSPITAL   (United States)

Author keywords

Apolipoprotein A 1 Milano; Cardiovascular risk; Cholesterol efflux capacity; Cholesteryl ester transfer protein inhibitors; High density lipoprotein functionality; Highdensity lipoprotein particles

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN;

BIOLOGICAL ACTIVITY; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HEART PROTECTION; HUMAN; MACROPHAGE; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; HUMANS; LIPOPROTEINS, HDL; RISK FACTORS;

EID: 84901626093     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000231     Document Type: Review

References (51)

1. O'Keefe JH Jr, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normal. J Am Coll Cardiol 2004;43:2142-6
2. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
3. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
4. Chapman MJ, Ginsberg HN, Amarenco P, et al European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management. Eur Heart J 2011;32:1345-61
5. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease - The Framingham Heart Study. Can J Cardiol 1988;4(suppl A): 5A-10A.
6. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
7. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000
8. Vergeer M, Holleboom AG, Kastelein JJ, et al. The HDL hypothesis: Does high-density lipoprotein protect from atherosclerosis?. J Lipid Res 2010;51:2058-73
9. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet 2012;380:572-80
10. van Capelleveen JC, Bochem AE, Motazacker MM, et al. Genetics of HDL-C: A causal link to atherosclerosis?. Curr Atheroscler Rep 2013; 15:326
11. Silbernagel G, Schöttker B, Appelbaum S, et al. High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J 2013;34:3563-71
12. Angeloni E, Paneni F, Landmesser U, et al. Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J 2013;34:3557-62
13. van Der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: Significance for cardiovascular risk: The IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008;51:634-42
14. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
15. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367:2089-99
16. Toth PP. Reverse cholesterol transport: High-density lipoprotein's magnificent mile. Curr Atheroscler Rep 2003;5:386-93
17. Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res 2004;95:764-72
18. Mineo C, Deguchi H, Griffin JH, et al. Endothelial and antithrombotic actions of HDL. Circ Res 2006;98:1352-64
19. Riwanto M, Landmesser U. High-density lipoproteins and endothelial functions: Mechanistic insights and alterations in cardiovascular disease. J Lipid Res 2013;54:3227-43
20. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-56
21. Kontush A, Lhomme M, Chapman MJ. Unraveling the complexities of the HDL lipidome. J Lipid Res 2013;54:2950-63
22. Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011;57:392-410
23. Gualandri V, Franceschini G, Sirtori CR, et al. AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 1985;37:1083-97
24. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: The Limone sul Garda study. Circulation 2001;103:1949-54
25. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003;290:2292-300
26. Ibanez B, Giannarelli C, Cimmino G, et al. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-Type). Atherosclerosis 2012;220:72-7
27. Morehouse LA, Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 2007;48:1263-72
28. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-15
29. Salonen JT, Salonen R, Seppänen K, et al. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction: A prospective population study in eastern Finnish men. Circulation 1991;84:129-39
30. Drexel H, Amann FW, Rentsch K, et al. Relation of the level of highdensity lipoprotein subfractions to the presence and extent of coronary artery disease. Am J Cardiol 1992;70:436-40
31. Freedman DS, Otvos JD, Jeyarajah EJ, et al. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18:1046-53
32. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002;90:89-94
33. Boekholdt SM, Arsenault BJ, Hovingh GK, et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-Treated patients: A meta-Analysis. Circulation 2013;128:1504-12
34. Parish S, Offer A, Clarke R, et al Heart Protection Study Collaborative Group. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 2012;125: 2469-78
35. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011;17:594-603
36. Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003;23:1881-8
37. Ishigami M, Yamashita S, Sakai N, et al. Large and cholesteryl esterrich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem 1994;116:257-62
38. Mackey RH, Greenland P, Goff DC Jr, et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2012;60:508-16
39. Rashedi N, Brennan D, Kastelein JJ, et al. Impact of cholesteryl ester transfer protein inhibition on nuclear magnetic resonance derived lipoprotein particle parameters (abstr). Atherosclerosis Supplements 2011;12:48
40. Ballantyne CM, Miller M, Niesor EJ, et al. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in Dyslipidemic patients: Results of a phase IIb dose-ranging study. Am Heart J 2012;163:515-21
41. Navab M, Imes SS, Hama SY, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88:2039-46
42. Fisher EA, Feig JE, Hewing B, et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2012;32:2813-20
43. Navab M, Reddy ST, Van Lenten BJ, et al. HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011;8:222-32
44. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758-67
45. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein Distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108: 2751-6
46. Nicholls SJ, Lundman P, Harmer JA, et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J Am Coll Cardiol 2006;48:715-20
47. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127-35
48. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010;30: 796-801
49. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: Key to the regression of atherosclerosis?. Circulation 2006;113:2548-55
50. Li XM, Tang WH, Mosior MK, et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013;33:1696-705
51. Akhabue E, Thiboutot J, Cheng JW, et al. New and emerging risk factors for coronary heart disease. Am J Med Sci 2014;347:151-8